Next Article in Journal
Factors Influencing the Duration of Rehabilitation in Infants with Torticollis—A Pilot Study
Previous Article in Journal
Atypical Complications during the Course of COVID-19: A Comprehensive Review
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Association between Ranolazine, Ischemic Preconditioning, and Cardioprotection in Patients Undergoing Scheduled Percutaneous Coronary Intervention

by
Konstantinos Kourtis
1,
Angeliki Bourazana
2,
Andrew Xanthopoulos
2,*,
Spyridon Skoularigkis
2,
Emmanouil Papadakis
1,
Sotirios Patsilinakos
1 and
John Skoularigis
2,*
1
Department of Cardiology, Konstantopouleio General Hospital, 14233 Athens, Greece
2
Department of Cardiology, University Hospital of Larissa, 41110 Larissa, Greece
*
Authors to whom correspondence should be addressed.
Medicina 2024, 60(1), 166; https://doi.org/10.3390/medicina60010166
Submission received: 6 December 2023 / Revised: 30 December 2023 / Accepted: 15 January 2024 / Published: 16 January 2024
(This article belongs to the Section Cardiology)

Abstract

Background and Objectives: Remote ischemic preconditioning (RIPC) has demonstrated efficacy in protecting against myocardial ischemia–reperfusion injury when applied before percutaneous coronary revascularization. Ranolazine, an anti-ischemic drug, has been utilized to minimize ischemic events in chronic angina patients. However, there is a lack of trials exploring the combined effects of ranolazine pretreatment and RIPC in patients undergoing percutaneous coronary interventions (PCIs). Materials and Methods: The present study is a prospective study which enrolled 150 patients scheduled for nonemergent percutaneous coronary revascularization. Three groups were formed: a control group undergoing only PCIs, an RIPC group with RIPC applied to either upper limb before the PCI (preconditioning group), and a group with RIPC before the PCI along with prior ranolazine treatment for stable angina (ranolazine group). Statistical analyses, including ANOVAs and Kruskal–Wallis tests, were conducted, with the Bonferroni correction for type I errors. A repeated-measures ANOVA assessed the changes in serum enzyme levels (SGOT, LDH, CRP, CPK, CK-MB, troponin I) over the follow-up. Statistical significance was set at p < 0.05. Results: The ranolazine group showed (A) significantly lower troponin I level increases compared to the control group for up to 24 h, (B) significantly lower CPK levels after 4, 10, and 24 h compared to the preconditioning group (p = 0.020, p = 0.020, and p = 0.019, respectively) and significantly lower CPK levels compared to the control group after 10 h (p = 0.050), and (C) significantly lower CK-MB levels after 10 h compared to the control group (p = 0.050). Conclusions: This study suggests that combining RIPC before scheduled coronary procedures with ranolazine pretreatment may be linked to reduced ischemia induction, as evidenced by lower myocardial enzyme levels.
Keywords: ranolazine; preconditioning; cardioprotection; percutaneous; coronary; intervention ranolazine; preconditioning; cardioprotection; percutaneous; coronary; intervention

Share and Cite

MDPI and ACS Style

Kourtis, K.; Bourazana, A.; Xanthopoulos, A.; Skoularigkis, S.; Papadakis, E.; Patsilinakos, S.; Skoularigis, J. Association between Ranolazine, Ischemic Preconditioning, and Cardioprotection in Patients Undergoing Scheduled Percutaneous Coronary Intervention. Medicina 2024, 60, 166. https://doi.org/10.3390/medicina60010166

AMA Style

Kourtis K, Bourazana A, Xanthopoulos A, Skoularigkis S, Papadakis E, Patsilinakos S, Skoularigis J. Association between Ranolazine, Ischemic Preconditioning, and Cardioprotection in Patients Undergoing Scheduled Percutaneous Coronary Intervention. Medicina. 2024; 60(1):166. https://doi.org/10.3390/medicina60010166

Chicago/Turabian Style

Kourtis, Konstantinos, Angeliki Bourazana, Andrew Xanthopoulos, Spyridon Skoularigkis, Emmanouil Papadakis, Sotirios Patsilinakos, and John Skoularigis. 2024. "Association between Ranolazine, Ischemic Preconditioning, and Cardioprotection in Patients Undergoing Scheduled Percutaneous Coronary Intervention" Medicina 60, no. 1: 166. https://doi.org/10.3390/medicina60010166

APA Style

Kourtis, K., Bourazana, A., Xanthopoulos, A., Skoularigkis, S., Papadakis, E., Patsilinakos, S., & Skoularigis, J. (2024). Association between Ranolazine, Ischemic Preconditioning, and Cardioprotection in Patients Undergoing Scheduled Percutaneous Coronary Intervention. Medicina, 60(1), 166. https://doi.org/10.3390/medicina60010166

Article Metrics

Back to TopTop